BRM Capital is a dynamic venture capital fund investing in early stage, Israel-related software, internet infrastructure, and communication companies. Their investment focus is on the Internet, mobile and mobile applications, digital media, online services, enterprise software, and medical device sectors and they also offer flexible, streamlined investment decision making. BRM headquartered in Tel Aviv, Israel enjoys a worldwide network of industry, strategic and financial experts.

BRM Capital

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Pontifax

BioStar Ventures is a venture capital company that offers private equity investment services to firms in the medical device technology services industries. It was founded in 2003 by Louis Cannon and is based in Michigan.

BioStar Capital

Edwards Lifesciences is a provider of science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives.

Edwards Lifesciences

Triventures is a global venture capital firm that invests in startups led by exceptional entrepreneurs. The fund identifies cross-industry breakthroughs that converge the best in class in health and non-health technologies such as insurtech and fintech for healthcare, e-commerce and cyber for healthcare, community-driven genomics, health data marketplaces, and more. Triventures’ team is comprised of key opinion leaders in healthcare, entrepreneurship, venturing and corporate business development and has decades of accumulated industry experience and relationships. Triventures was founded in 2010 and is headquartered in Herzliya, Tel Aviv, Israel with offices in California, U.S.

Triventures

Pura Vida Investments is a fundamentally driven, market neutral healthcare-focused investment vehicle. The objective of the firm is to identify and capitalize on structural changes in the healthcare landscape and on inflections in company specific valuations. The firm strives to look past day-to-day volatility and to hone in on major value shifts over the medium to longer term.  The firm’s portfolio is managed by Efrem Kamen and Doron Junger MD and is run in a market neutral fashion, investing across most areas of healthcare, including medical devices, biotechnology, pharmaceuticals, tools, life sciences and healthcare services. The Fund has an optional 10% allocation to designated investments, allowing participation in private and certain illiquid public securities, which is managed by Frank Litvack MD.

Pura Vida Investments

Johnson & Johnson Innovation is a center for science and business experts to collaborate with innovators to incorporate science into healthcare solutions, including medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals. It is focused on the advancement of new healthcare solutions in the consumer, pharmaceutical, and medical devices and diagnostics sectors.’ The company provides financing tools that include early-stage research funding, seed funding, equity investments, licensing, and collaborations. Additionally, it offers its partners access to international markets, pricing and reimbursement, market testing, company creation services, and more. They conduct their activities with the help of regional incubators, satellite operations, single bench tops, modular labs, office space for entrepreneurs, and a year-round curriculum focused on business and drug development. Johnson & Johnson Innovation is a subsidiary of [Johnson & Johnson](http://www.crunchbase.com/organization/johnson-johnson)  and its centers are located in Boston, California, London, and Shanghai.

Johnson & Johnson Robotics and Digital Solutions

Deerfield is an investment management firm. They provide a healthcare ecosystem through information and investment. They also provide private and public investments across the life science, medical device, diagnostic, digital health, and health service industries.

Deerfield

Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive international experience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017).  Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.

Endeavour Vision

Aperture Venture Partners is a venture capital group committed to working with exceptional entrepreneurs to tackle significant problems and create major new opportunities. They work with companies across a variety of sectors, primarily within the healthcare and healthy living industries. Their initial investment size ranges between $1 million and $5 million and they invest nationally. Their principals have been entrepreneurial leaders in the healthcare and investment industries over the past 30 years. They have successfully invested more than $1 billion and founded companies that have had combined revenues greater than $1 billion.

Aperture Venture Partners

Israel Secondary Fund (''ISF'') acquires interests in Israel related funds and private companies from investors, founders and employees. Since the inception of the secondary market in Israel in 1998, ISF's partners have played a major role in it, executing dozens of transactions. Our investment professionals have experience in a broad range of secondary transactions as well as hands on experience as partners in venture capital and private equity firms. We have collaborated with the majority of PE and VC funds active in Israel, international & Israeli institutions and have formed close relationships with employees, founders and managers of companies.  We believe in the value ISF brings to stakeholders in the Venture Capital and Private Equity community. Creative, discrete and straightforward with a view for long term partnerships and growth, is our way of doing business.  What We do:  Limited Partners Positions - ISF acquires Limited Partners interests in Israel related VC & PE funds with diversified portfolios. We tailor the transaction to suit the requirements of the sellers and assume future capital commitments.  Secondary Direct - ISF acquires interests in Israel-related private companies and portfolios. Sellers include funds, investors, founders and employees. When needed we create Special Purpose Vehicles together with existing GPs or Managers.   Structured Secondaries - ISF provides customized solutions, to provide additional capital to Funds and to Limited Partners seeking to reduce risk. When needed we work with fund management and LPs to construct annex funds or other special vehicles.

Israel Secondary Fund (ISF)

Established in 2015, Quark Venture Inc. is a venture capital investment firm, headquartered in Vancouver, Canada, and is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.

Quark Venture

Johnson & Johnson Innovation accelerates early-stage innovation through strategic collaboration. It connects potential collaborators to resources with the goal of assisting them in advancing transformation science and technology across the pharmaceutical, medical device, and consumer healthcare spectrums.

Johnson & Johnson Innovation – JJDC

V-Wave

V-Wave is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with Chronic Heart Failure (HF). V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment. V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity, and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing, and bringing to market multiple implantable cardiovascular devices.

V-Wave focuses on developing interatrial shunt devices for treating heart failure (HF). Its flagship product, the Ventura Interatrial Shunt, is an investigational device designed in an hourglass shape to reduce elevated left atrial pressure, a key driver of pulmonary congestion and hospitalizations in HF patients. The shunt creates a controlled amount of blood flow between the left and right atria, lowering left atrial pressure while protecting the right heart from volume overload. It is implanted through a minimally invasive catheter-based procedure, with patients typically discharged after an overnight stay.

Pushing the envelope in MedTech with emerging technologies

Next-gen Medical Devices

Johnson & Johnson Completes Purchase Of Israeli Startup V-Wave

Johnson & Johnson

To extend Johnson & Johnson MedTech’s position as an innovation leader in addressing cardiovascular disease.

Companies that develop implantable medical devices designed to be surgically placed inside the human body, either temporarily or permanently, including devices such as pacemakers, artificial joints, stents, and cochlear implants

V-Wave focuses on developing interatrial shunt devices for treating heart failure (HF). Its flagship product, the Ventura Interatrial Shunt, is an investigational device designed in an hourglass shape to reduce elevated left atrial pressure, a key driver of pulmonary congestion and hospitalizations in HF patients. The shunt creates a controlled amount of blood flow between the left and right atria, lowering left atrial pressure while protecting the right heart from volume overload. It is implanted through a minimally invasive catheter-based procedure, with patients typically discharged after an overnight stay.The Ventura Shunt has received breakthrough device designation from the FDA and CE Marking in the EU. As of July 2024, V-Wave was undergoing trial and was yet to obtain FDA approval. In April 2024, V-Wave announced positive results from its RELIEVE-HF trial.

Proximie is a global health technology platform that combines telepresence, augmented reality, machine learning, and artificial intelligence to enable surgeons to virtually "scrub in" to any operating room from anywhere in the world. The company's core product is a web-based software that allows surgeons to collaborate remotely by sharing live video streams of surgeries from up to four camera perspectives, along with medical scans. It features augmented reality tools that enable surgeons to draw instructions or annotations on the shared screen, providing real-time guidance during procedures.
Founded in 2016 by Dr. Nadine Hachach-Haram, a plastic surgeon, Proximie aims to democratize access to surgical expertise by connecting surgeons across the globe. Its technology helps overcome barriers caused by limited staff, time, and resources, enabling healthcare organizations to improve patient outcomes, safety, and productivity. Proximie's platform also captures data from procedures, creating a secure library that can be used for training, debriefing, and advancing surgical techniques.
As of 2023, Proximie has been used in over 13,000 surgeries across more than 500 hospitals in over 100 countries. The company has partnerships with major healthcare providers, medical device companies, and educational institutions, leveraging its technology for remote mentoring, proctoring, and accelerating the adoption of new surgical products and techniques.

Proximie

Convergent Dental, Inc. is a privately owned dental equipment and technology company. Its flagship product, Solea, is the only CO2 laser cleared by the FDA for all-tissue indications, delivering an anesthesia-free, blood-free, and suture-free experience for dentists and patients. Solea represents a breakthrough in dental laser technology, offering a distinct experience compared to traditional instruments or earlier laser treatments.
Solea is a novel 9.3-micron CO2 laser that nears the peak absorption of hydroxyapatite (enamel), enabling it to vaporize enamel with speed and precision. This unique wavelength, coupled with computer-controlled motors (galvos) that manipulate the beam thousands of times per second, allows dentists to perform procedures ranging from hard tissue to soft tissue with total control and efficiency.
A key feature of Solea is its variable-speed foot pedal, which lets dentists seamlessly transition from hard to soft tissue by adjusting the pressure applied. This intuitive design streamlines the learning curve for dentists accustomed to using a drill. Solea's three ergonomic handpieces – Contra-Angle, Straight, and Ultraguide – further enhance its versatility across various procedures.
Solea not only improves patient experiences but also offers practice benefits such as increased productivity, new patient flow, and efficiency gains. In October 2022, Convergent Dental received FDA clearance for Solea to aid in reducing mineral loss in dental enamel, protecting teeth against acid attack and caries development. This breakthrough application was commercially launched in November 2023 under the name Solea Protect.

Convergent Dental

Ossio is an orthopedic fixation technology company that has developed OSSIOfiber Intelligent Bone Regeneration Technology, a breakthrough implant material designed to securely fixate and fully integrate into the body's native anatomy without leaving any permanent hardware behind. This technology addresses the limitations of conventional metal and resorbable implants, combining unparalleled mechanical strength with natural bone healing.
Made from a proprietary mineral fiber matrix held together by a naturally degradable polymer, OSSIOfiber implants provide surgeons with a more biologically friendly way to restore patient stability and mobility. These implants are engineered to provide the strength required for functional fixation while allowing full integration into the native bone without adverse biological response.
Ossio's product portfolio includes compression screws, trimmable fixation nails, hammertoe fixation systems, suture anchors, and compression staples, all made with OSSIOfiber technology. These implants have received multiple FDA clearances since 2019, and the company has initiated commercialization of its products in the US. As of March 2022, over 6,000 implantations of OSSIOfiber products had been performed, demonstrating adoption of this innovative technology.
OSSIOfiber Intelligent Bone Regeneration Technology can address various surgical applications through the manufacturing of implant designs like nails, screws, staples, anchors, and plates. Ossio plans to pursue multiple applications in distal extremities, trauma, sports, reconstruction, pediatrics, and spine segments.
In February 2023, Ossio launched the world's first and only non-permanent compression staple made with OSSIOfiber technology, designed for predictable bone in-growth, regeneration, and replacement.

Ossio

Casana is a healthcare technology company that has developed the Heart Seat, an innovative toilet seat that enables effortless, integrated, and consistent in-home health monitoring. The Heart Seat is a replacement for a standard toilet seat and is designed to measure key clinical parameters such as heart rate, blood oxygen saturation (SpO2), and blood pressure.
In May 2023, Casana received FDA clearance for the Heart Seat to measure heart rate and SpO2 in adults aged 22 years and older, weighing between 90 to 350 pounds. The company plans to file for additional indications, including systolic and diastolic blood pressure, with the goal of launching the product in the market by the end of 2023.
The Heart Seat is equipped with sensors that passively capture health data whenever the seat is used, eliminating the need for user compliance or behavior changes. The data is automatically uploaded to the Casana Cloud, where it can be viewed by healthcare providers, enabling them to monitor patients' health trends and respond to changes in near real-time.
Casana's technology allows for the effortless collection of consistent and reliable data, assisting medical teams in monitoring chronic conditions beyond the hospital or physician's office. The company aims to unlock a new category in healthcare technologies that enables seamless, integrated, and continuous in-home health monitoring.
In January 2022, Casana was acquired by an undisclosed entity, further accelerating the commercialization of the Heart Seat.

Casana

Neurent Medical is a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, particularly chronic rhinitis. The company's flagship product is the NEUROMARK System, a device that received US Food and Drug Administration (FDA) 510(k) clearance in October 2021.
The NEUROMARK System is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This alleviates chronic rhinitis symptoms such as persistent congestion, rhinorrhea (runny nose), swelling of the mucosal membrane, sneezing, and nasal itching. The system's unique flexible leaflet design and proprietary smart algorithms enable precise neurolysis (disruption) of the posterior nasal nerves (PNN) and accessory pathways, accommodating a range of patient anatomies while maintaining mucosal and vascular integrity.
Neurent Medical announced the limited market release of the NEUROMARK System in the US in February 2023, following the establishment of a new Category I Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for PNN procedures, effective January 2024. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) also endorsed the PNN procedure in 2023.

Neurent Medical

Companies that develop diagnostic devices used in a hospital setting to identify a disease, condition, or injury, such as imaging systems and endoscopes

Companies that develop non-surgical devices that are used in a procedure or intervention to cure or relieve a patient from an illness or disease such as laser treatments, dental equipment, and wound care management

Companies that develop monitoring devices that are used in a hospital setting to measure patient vital signs and ensure patient well-being post-treatment, such as cardiac and respiratory monitoring systems

Providers of software that enhances the functionality of medical device hardware (diagnosis, treatment, and monitoring)

Companies that develop surgical devices involving invasive interventions (cutting into a patient's body tissues) to treat, cure, or relieve a patient of an illness or disease

Companies that develop devices to administer pharmaceutical substances into a patient's body, ensuring controlled release or targeted delivery, specifically for use in clinical settings to treat or manage medical conditions effectively

Providers of software that helps manage risks, ensure quality, and streamline audit processes during medical device development

IoT connects devices to EHR systems for precise patient diagnosis and treatment support

Devices are linked to software platforms that use digital technologies such as AI/ML and VR

Startups leverage AI/ML and deep learning to support patient diagnosis and early detection

V-Wave

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless